The reported role of Sgk3 in driving human cancers in the absence of Akt hyperactivation is then also reconcilable with this model and reinforces the potential value of Sgk3 as a therapeutic target either as a monotherapy or in combination with Akt inhibitors. The gene discussed is AKT1; the disease is cancer.